The Only 3 Things in Moderna's Q3 Update That Really Matter
Moderna (NASDAQ: MRNA) blew it with its third-quarter earnings update on nearly every front. The company reported revenue of $5 billion, far below the consensus Wall Street estimate of $6.2 billion. It posted earnings of $3.3 billion, or $7.70 per diluted share. The average analysts' estimate was for earnings of $9.05 per share. Moderna also cut its full-year 2021 sales guidance from $20 billion to between $15 billion and $18 billion.
Unsurprisingly, the vaccine stock plunged 17% in intraday trading on Thursday. But investors actually shouldn't focus much on the big revenue and earnings misses. Here are the only three things in Moderna's Q3 update that really matter.
Image source: Getty Images.
Source Fool.com
